Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BMS-986368

Phase 2Small molecule

Bristol-Myers Squibb

1

Indications

5

Total Trials

3

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Study completion

NCT07700329

Q2 2027

Phase 2Recruiting

Multiple Sclerosis Spasticity

NCT06782490

Q1 2028

Phase 2Recruiting

Agitation

NCT06808984

Clinical

Trials by Indication[1]

Elderly Participants1 trial

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06411730·56 enrolled

Drug1 trial

A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06170723·32 enrolled

Multiple Sclerosis Spasticity1 trial

A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06782490·200 enrolled

Agitation1 trial

A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Agitation in Participants With Alzheimer's Disease (BALANCE-AAD-1)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06808984·120 enrolled

Unspecified1 trial

A Phase 1, Double-Blinded, Randomized, Placebo-Controlled, Two Parallel Cohort Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT07700329·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for BMS-986368. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986368 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986368. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

Related News